Australian company Emyria (ASX:EMD) has announced interim clinical results from an analysis of its MDMA-assisted therapy for post-traumatic stress disorder program, which commenced in October 2023. …
Emyria announces interim clinical trial results for PTSD program
September 2, 2024 Australian Biotech
Latest Video
New Stories
-
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
Your success makes you a target and take it as a compliment
September 16, 2026 - -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News